

July 2021

BCBSAL Prior Authorization Utilization Management

Prior Authorization

Certain drugs require prior authorization to help promote safe, quality and affordable pharmacy care. Your doctor will need to submit a prior authorization request to Prime Therapeutics, which must be approved before you can continue to receive coverage for these drugs.

The Prior Authorization form that your physician will need to complete to request an approval can be found on the MyPrime website.

Quantity Limit Consideration

Within the Prior Authorization program, Quantity Limit may apply. If there is medical reason why you need an amount that is greater than what is allowed, your physician can fill out a Quantity Limit prior authorization form for you and send it to Prime Therapeutics. This form can be found on the MyPrime.com website.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
Acute Migraine Agents		NURTEC
Acute Migraine Agents		REYVOW
Acute Migraine Agents		UBRELVY
Afrezza		AFREZZA
Amantadine ER		GOCOVRI
Amantadine ER		OSMOLEX ER
Amifampridine	Preferred Product: Ruzurgi	FIRDAPSE
Amifampridine	Preferred Product: Ruzurgi	RUZURGI
Ampyra		AMPYRA
Ampyra		dalfampridine er
Androgen/Anabolic Steroids		ANADROL-50
Androgen/Anabolic Steroids		ANDRODERM
Androgen/Anabolic Steroids		ANDROGEL
Androgen/Anabolic Steroids		ANDROGEL PUMP

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner™. NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
Androgen/Anabolic Steroids		danazol
Androgen/Anabolic Steroids		FORTESTA
Androgen/Anabolic Steroids		JATENZO
Androgen/Anabolic Steroids		METHITEST
Androgen/Anabolic Steroids		METHYLTESTOSTERONE
Androgen/Anabolic Steroids		NATESTO
Androgen/Anabolic Steroids		oxandrolone
Androgen/Anabolic Steroids		STRIANT
Androgen/Anabolic Steroids		TESTIM
Androgen/Anabolic Steroids		TESTOSTERONE
Androgen/Anabolic Steroids		TESTOSTERONE PUMP
Androgen/Anabolic Steroids		testosterone topical solution
Androgen/Anabolic Steroids		VOGELXO
Androgen/Anabolic Steroids		VOGELXO PUMP
Antifungal (Ciclopirox/Efinaconazole /Tavaborole)		JUBLIA
Antifungal (Ciclopirox/Efinaconazole /Tavaborole)		KERYDIN
Antifungal (Ciclopirox/Efinaconazole /Tavaborole)		tavaborole
Antifungal (Ciclopirox/Efinaconazole /Tavaborole)		ciclodan

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
Antifungal (Ciclopirox/Efinaconazole /Tavaborole)		ciclopirox nail lacquer
Antifungal (Ciclopirox/Efinaconazole /Tavaborole)		PENLAC NAIL LACQUER
Arikayce		ARIKAYCE
ATTR Amyloidosis		TEGSEDI
ATTR Amyloidosis		VYNDAMAX
ATTR Amyloidosis		VYNDAQEL
Baclofen		OZOBAX
Bempedoic Acid		NEXLETOL
Bempedoic Acid		NEXLIZET
Biologic Immunomodulators	Preferred Products: Refer to Policy	ACTEMRA
Biologic Immunomodulators	Preferred Products: Refer to Policy	ACTEMRA ACTPEN
Biologic Immunomodulators	Preferred Products: Refer to Policy	CIMZIA
Biologic Immunomodulators	Preferred Products: Refer to Policy	CIMZIA STARTER KIT
Biologic Immunomodulators	Preferred Products: Refer to Policy	COSENTYX
Biologic Immunomodulators	Preferred Products: Refer to Policy	COSENTYX SENSOREADY PEN
Biologic Immunomodulators	Preferred Products: Refer to Policy	ENBREL
Biologic Immunomodulators	Preferred Products: Refer to Policy	ENBREL MINI
Biologic Immunomodulators	Preferred Products: Refer to Policy	ENBREL SURECLICK
Biologic Immunomodulators	Preferred Products: Refer to Policy	HUMIRA
Biologic Immunomodulators	Preferred Products: Refer to Policy	HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK
Biologic Immunomodulators	Preferred Products: Refer to Policy	HUMIRA PEN
Biologic Immunomodulators	Preferred Products: Refer to Policy	HUMIRA PEN-CD/UC/HS STARTER
Biologic Immunomodulators	Preferred Products: Refer to Policy	HUMIRA PEN-PEDIATRIC UC STARTER PACK

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
Biologic Immunomodulators	Preferred Products: Refer to Policy	HUMIRA PEN-PS/UV STARTER
Biologic Immunomodulators	Preferred Products: Refer to Policy	KEVZARA
Biologic Immunomodulators	Preferred Products: Refer to Policy	KINERET
Biologic Immunomodulators	Preferred Products: Refer to Policy	OLUMIANT
Biologic Immunomodulators	Preferred Products: Refer to Policy	ORENCIA
Biologic Immunomodulators	Preferred Products: Refer to Policy	ORENCIA CLICKJECT
Biologic Immunomodulators	Preferred Products: Refer to Policy	RINVOQ
Biologic Immunomodulators	Preferred Products: Refer to Policy	SILIQ
Biologic Immunomodulators	Preferred Products: Refer to Policy	SIMPONI
Biologic Immunomodulators	Preferred Products: Refer to Policy	SKYRIZI
Biologic Immunomodulators	Preferred Products: Refer to Policy	STELARA
Biologic Immunomodulators	Preferred Products: Refer to Policy	TALTZ
Biologic Immunomodulators	Preferred Products: Refer to Policy	TREMFYA
Biologic Immunomodulators	Preferred Products: Refer to Policy	XELJANZ
Biologic Immunomodulators	Preferred Products: Refer to Policy	XELJANZ XR
Bonjesta/Diclegis		BONJESTA
Bonjesta/Diclegis		DICLEGIS
Bonjesta/Diclegis		doxylamine succinate/pyridoxine hydrochloride
Buprenorphine Opioid Dependence		buprenorphine hcl
Cannabidiol		EPIDIOLEX
Carbaglu		CARBAGLU
CFTR		KALYDECO
CFTR		ORKAMBI
CFTR		SYMDEKO

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
CFTR		TRIKAFTA
CGRP	Preferred Products: Aimovig, Emgality	AIMOVIG
CGRP	Preferred Products: Aimovig, Emgality	AJOVY
CGRP	Preferred Products: Aimovig, Emgality	EMGALITY
Constipation Agents	Preferred Products: Symproic, Trulance	AMITIZA
Constipation Agents	Preferred Products: Symproic, Trulance	LINZESS
Constipation Agents	Preferred Products: Symproic, Trulance	LUBIPROSTONE
Constipation Agents	Preferred Products: Symproic, Trulance	MOTEGRITY
Constipation Agents	Preferred Products: Symproic, Trulance	MOVANTIK
Constipation Agents	Preferred Products: Symproic, Trulance	RELISTOR
Constipation Agents	Preferred Products: Symproic, Trulance	SYMPROIC
Constipation Agents	Preferred Products: Symproic, Trulance	TRULANCE
Constipation Agents	Preferred Products: Symproic, Trulance	ZELNORM
Corticotropin		ACTHAR
Dojolvi		DOJOLVI
Elagolix		ORIAHNN
Elagolix		ORILISSA
Elmiron		ELMIRON
Emflaza		EMFLAZA
Endari		ENDARI
Enspryng		ENSPRYNG
Eysuvis		EYSUVIS
Fintepla		FINTEPLA
Flector		DICLOFENAC EPOLAMINE
Flector		FLECTOR
Galafold		GALAFOLD
Gattex		GATTEX
Growth Hormone	Preferred Product: Norditropin	GENOTROPIN
Growth Hormone	Preferred Product: Norditropin	GENOTROPIN MINQUICK
Growth Hormone	Preferred Product: Norditropin	HUMATROPE
Growth Hormone	Preferred Product: Norditropin	HUMATROPE COMBO PACK
Growth Hormone	Preferred Product: Norditropin	NORDITROPIN FLEXPOR
Growth Hormone	Preferred Product: Norditropin	NUTROPIN AQ NUSPIN 10
Growth Hormone	Preferred Product: Norditropin	NUTROPIN AQ NUSPIN 20
Growth Hormone	Preferred Product: Norditropin	NUTROPIN AQ NUSPIN 5
Growth Hormone	Preferred Product: Norditropin	OMNITROPE
Growth Hormone	Preferred Product: Norditropin	SAIZEN

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
Growth Hormone	Preferred Product: Norditropin	SAIZENPREP RECONSTITUTIONKIT
Growth Hormone	Preferred Product: Norditropin	SEROSTIM
Growth Hormone	Preferred Product: Norditropin	ZOMACTON
Growth Hormone	Preferred Product: Norditropin	ZORBTIVE
HCN Channel Blocker		CORLANOR
Hemophilia Agents		SEVENFACT
Hemophilia Agents		ADVATE
Hemophilia Agents		ADYNOVATE
Hemophilia Agents		AFSTYLA
Hemophilia Agents		ALPHANATE
Hemophilia Agents		ALPHANATE/VON WILLEBRAND FACTOR COMPLEX/HUMAN
Hemophilia Agents		ALPHANINE SD
Hemophilia Agents		ALPROLIX
Hemophilia Agents		BENEFIX
Hemophilia Agents		COAGADEX
Hemophilia Agents		CORIFACT
Hemophilia Agents		ELOCTATE
Hemophilia Agents		ESPEROCT
Hemophilia Agents		FEIBA
Hemophilia Agents		HELIXATE FS
Hemophilia Agents		HEMLIBRA
Hemophilia Agents		HEMOFIL M
Hemophilia Agents		HUMATE-P
Hemophilia Agents		IDELVION
Hemophilia Agents		IXINITY
Hemophilia Agents		JIVI
Hemophilia Agents		KOATE
Hemophilia Agents		KOATE-DVI
Hemophilia Agents		KOGENATE FS
Hemophilia Agents		KOVALTRY
Hemophilia Agents		MONOCLATE-P
Hemophilia Agents		MONONINE
Hemophilia Agents		NOVOEIGHT
Hemophilia Agents		NOVOSEVEN RT
Hemophilia Agents		NUWIQ
Hemophilia Agents		OBIZUR

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
Hemophilia Agents		PROFILNINE
Hemophilia Agents		PROFILNINE SD
Hemophilia Agents		REBINYN
Hemophilia Agents		RECOMBINATE
Hemophilia Agents		RIXUBIS
Hemophilia Agents		TRETTEN
Hemophilia Agents		VONVENDI
Hemophilia Agents		WILATE
Hemophilia Agents		XYNTHA
Hemophilia Agents		XYNTHA SOLOFUSE
Hepatitis C Direct Acting Antivirals	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi	EPCLUSA
Hepatitis C Direct Acting Antivirals	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi	HARVONI
Hepatitis C Direct Acting Antivirals	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi	LEDIPASVIR/SOFOSBUVIR
Hepatitis C Direct Acting Antivirals	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi	MAVYRET
Hepatitis C Direct Acting Antivirals	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi	SOFOSBUVIR/VELPATASVIR
Hepatitis C Direct Acting Antivirals	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi	SOVALDI
Hepatitis C Direct Acting Antivirals	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi	VIEKIRA PAK
Hepatitis C Direct Acting Antivirals	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi	VOSEVI

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
	generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi	
Hepatitis C Direct Acting Antivirals	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi	ZEPATIER
Hereditary Angioedema		BERINERT
Hereditary Angioedema		FIRAZYR
Hereditary Angioedema		HAEGARDA
Hereditary Angioedema		icatibant acetate
Hereditary Angioedema		KALBITOR
Hereditary Angioedema		ORLADEYO
Hereditary Angioedema		RUCONEST
Hereditary Angioedema		TAKHZYRO
Hetlioz		HETLIOZ
Hetlioz		HETLIOZ LQ
HoFH Agents		JUXTAPID
HSDD		ADDYI
HSDD		VYLEESI
Hyperhidrosis		QBREXZA
Imcivree		IMCIVREE
Inhaled Antibiotics		BETHKIS
Inhaled Antibiotics		CAYSTON
Inhaled Antibiotics		KITABIS PAK
Inhaled Antibiotics		TOBI
Inhaled Antibiotics		TOBI PODHALER
Inhaled Antibiotics		TOBRAMYCIN
Interleukin (IL)-1 Inhibitors		ARCALYST
Interleukin (IL)-1 Inhibitors		ILARIS
Interleukin (IL)-4 Inhibitors		DUPIXENT
Interleukin (IL)-5 Inhibitors		FASENRA PEN
Interleukin (IL)-5 Inhibitors		NUCALA
Interstitial Lung Disease		ESBRIET
Interstitial Lung Disease		OFEV

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
Isturisa		ISTURISA
Jynarque		JYNARQUE
Keveyis		KEVEYIS
Korlym		KORLYM
Lucemyra		LUCEMYRA
Lupus		BENLYSTA
Lupus		LUPKYNIS
Lyrica CR		LYRICA CR
Myalept		MYALEPT
Natpara		NATPARA
Neurotrophic Keratitis		OXERVATE
Nocturia		NOC DURNA
Nocturia		NOCTIVA
Northera		droxidopa
Northera		NORTHERA
Ocaliva		OCALIVA
Ophthalmic Immunomodulators		CEQUA
Ophthalmic Immunomodulators		RESTASIS
Ophthalmic Immunomodulators		RESTASIS MULTIDOSE
Ophthalmic Immunomodulators		XIIDRA
Opioids ER		ARYMO ER
Opioids ER		BELBUCA
Opioids ER		buprenorphine
Opioids ER		BUTRANS
Opioids ER		CONZIP
Opioids ER		DURAGESIC
Opioids ER		EMBEDA
Opioids ER		fentanyl
Opioids ER		hydrocodone bitartrate er
Opioids ER		hydromorphone hcl er
Opioids ER		hydromorphone hydrochloride er
Opioids ER		HYSINGLA ER
Opioids ER		KADIAN
Opioids ER		MORPHABOND ER

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
Opioids ER		MORPHINE SULFATE ER
Opioids ER		MS CONTIN
Opioids ER		NUCYN TA ER
Opioids ER		OXYCODONE HCL ER
Opioids ER		OXYCODONE HYDROCHLORIDE ER
Opioids ER		OXYCONTIN
Opioids ER		OXYMORPHONE HYDROCHLORIDE ER
Opioids ER		OXYMORPHONE HYDROCHLORIDEER
Opioids ER		TRAMADOL HCL ER
Opioids ER		XTAMPZA ER
Opioids ER		ZOHYDRO ER
Opioids IR Duration Limit		ACETAMINOPHEN/CAFFEINE/DIHYDR OCODEINE
Opioids IR Duration Limit		acetaminophen/codeine
Opioids IR Duration Limit		acetaminophen/codeine phosphate
Opioids IR Duration Limit		APADAZ
Opioids IR Duration Limit		ascomp/codeine
Opioids IR Duration Limit		BENZHYDROCODONE/ACETAMINOP HEN
Opioids IR Duration Limit		butalbital/acetaminophen/caffeine/c odeine
Opioids IR Duration Limit		butalbital/aspirin/caffeine/codeine
Opioids IR Duration Limit		butorphanol tartrate
Opioids IR Duration Limit		CODEINE SULFATE
Opioids IR Duration Limit		DILAUDID
Opioids IR Duration Limit		DOLOPHINE
Opioids IR Duration Limit		dvorah
Opioids IR Duration Limit		endocet
Opioids IR Duration Limit		FIORICET/CODEINE
Opioids IR Duration Limit		FIORINAL/CODEINE #3
Opioids IR Duration Limit		hydrocodone bitartrate/acetaminophen
Opioids IR Duration Limit		hydrocodone/acetaminophen
Opioids IR Duration Limit		hydrocodone/ibuprofen
Opioids IR Duration Limit		hydromorphone hcl
Opioids IR Duration Limit		IBUDONE
Opioids IR Duration Limit		levorphanol tartrate
Opioids IR Duration Limit		lorcet

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
Opioids IR Duration Limit		lorcet hd
Opioids IR Duration Limit		lorcet plus
Opioids IR Duration Limit		LORTAB
Opioids IR Duration Limit		MEPERIDINE HCL
Opioids IR Duration Limit		METHADONE HCL
Opioids IR Duration Limit		methadone hcl intensol
Opioids IR Duration Limit		methadone hydrochloride
Opioids IR Duration Limit		METHADOSE
Opioids IR Duration Limit		METHADOSE SUGAR-FREE
Opioids IR Duration Limit		MORPHINE SULFATE
Opioids IR Duration Limit		NALOCET
Opioids IR Duration Limit		NORCO
Opioids IR Duration Limit		NUCYNTA
Opioids IR Duration Limit		OPANA
Opioids IR Duration Limit		OXAYDO
Opioids IR Duration Limit		oxycodone hcl
Opioids IR Duration Limit		oxycodone hydrochloride
Opioids IR Duration Limit		OXYCODONE HYDROCHLORIDE/ACETAMINOPHEN
Opioids IR Duration Limit		OXYCODONE/ACETAMINOPHEN
Opioids IR Duration Limit		OXYCODONE/ASPIRIN
Opioids IR Duration Limit		OXYCODONE/IBUPROFEN
Opioids IR Duration Limit		oxymorphone hydrochloride
Opioids IR Duration Limit		pentazocine/naloxone hcl
Opioids IR Duration Limit		PERCOCET
Opioids IR Duration Limit		PRIMLEV
Opioids IR Duration Limit		PROLATE
Opioids IR Duration Limit		QDOLO
Opioids IR Duration Limit		ROXICODONE
Opioids IR Duration Limit		tramadol hcl
Opioids IR Duration Limit		TRAMADOL HYDROCHLORIDE
Opioids IR Duration Limit		tramadol hydrochloride/acetaminophen
Opioids IR Duration Limit		TREZIX
Opioids IR Duration Limit		TYLENOL/CODEINE #2
Opioids IR Duration Limit		TYLENOL/CODEINE #3
Opioids IR Duration Limit		TYLENOL/CODEINE #4

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
Opioids IR Duration Limit		ULTRACET
Opioids IR Duration Limit		ULTRAM
Oral PAH Agents		ADCIRCA
Oral PAH Agents		ADEMPAS
Oral PAH Agents		alyq
Oral PAH Agents		ambrisentan
Oral PAH Agents		bosentan
Oral PAH Agents		LETAIRIS
Oral PAH Agents		OPSUMIT
Oral PAH Agents		ORENITRAM
Oral PAH Agents		REVATIO
Oral PAH Agents		sildenafil citrate
Oral PAH Agents		tadalafil
Oral PAH Agents		TRACLEER
Oral PAH Agents		TYVASO
Oral PAH Agents		TYVASO REFILL
Oral PAH Agents		TYVASO STARTER
Oral PAH Agents		UPTRAVI
Oral PAH Agents		VENTAVIS
Otezla		OTEZLA
Oxbryta		OXBRYTA
Oxybate		XYREM
Oxybate		XYWAV
Parathyroid Hormone Analog for Osteoporosis	Preferred Product: Tymlos	FORTEO
Parathyroid Hormone Analog for Osteoporosis	Preferred Product: Tymlos	TERIPARATIDE
Parathyroid Hormone Analog for Osteoporosis	Preferred Product: Tymlos	TYMLOS
PCSK-9 Inhibitors	Preferred Product: Repatha	PRALUENT
PCSK-9 Inhibitors	Preferred Product: Repatha	REPATHA
PCSK-9 Inhibitors	Preferred Product: Repatha	REPATHA PUSHTRONEX SYSTEM
PCSK-9 Inhibitors	Preferred Product: Repatha	REPATHA SURECLICK
Peanut Allergy		PALFORZIA INITIAL DOSE ESCALATION
Peanut Allergy		PALFORZIA LEVEL 1
Peanut Allergy		PALFORZIA LEVEL 10

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
Peanut Allergy		PALFORZIA LEVEL 11 (MAINTENANCE)
Peanut Allergy		PALFORZIA LEVEL 11 (TITRATION)
Peanut Allergy		PALFORZIA LEVEL 2
Peanut Allergy		PALFORZIA LEVEL 3
Peanut Allergy		PALFORZIA LEVEL 4
Peanut Allergy		PALFORZIA LEVEL 5
Peanut Allergy		PALFORZIA LEVEL 6
Peanut Allergy		PALFORZIA LEVEL 7
Peanut Allergy		PALFORZIA LEVEL 8
Peanut Allergy		PALFORZIA LEVEL 9
Peginterferon		PEGASYS
Peginterferon		PEGASYS PROCLICK
Peginterferon		PEGINTRON
Phenylketonuria		KUVAN
Phenylketonuria		PALYNZIQ
Phenylketonuria		sapropterin dihydrochloride
Procysbi		PROCYSBI
Pseudobulbar Affect		NUEDEXTA
Riluzole		RILUTEK
Riluzole		TIGLUTIK
Risdiplam		EVRYSDI
SA Oncology		abiraterone acetate
SA Oncology		AFINITOR
SA Oncology		AFINITOR DISPERZ
SA Oncology		ALECENSA
SA Oncology		ALUNBRIG
SA Oncology		AYVAKIT
SA Oncology		BALVERSA
SA Oncology		bexarotene
SA Oncology	Preferred Agents: generic imatinib, Sprycel	BOSULIF
SA Oncology		BRAFTOVI
SA Oncology		BRUKINSA
SA Oncology		CABOMETYX
SA Oncology		CALQUENCE
SA Oncology		capecitabine
SA Oncology		CAPRELSA

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
SA Oncology		COMETRIQ
SA Oncology		COPIKTRA
SA Oncology		COTELLIC
SA Oncology		DAURISMO
SA Oncology		ERIVEDGE
SA Oncology		ERLEADA
SA Oncology		erlotinib hydrochloride
SA Oncology		everolimus
SA Oncology		FARYDAK
SA Oncology		FOTIVDA
SA Oncology		GAVRETO
SA Oncology		GILOTRIF
SA Oncology		GLEEVEC
SA Oncology		HYCAMTIN
SA Oncology		IBRANCE
SA Oncology		ICLUSIG
SA Oncology		IDHIFA
SA Oncology		imatinib mesylate
SA Oncology		IMBRUVICA
SA Oncology		INLYTA
SA Oncology		INQOVI
SA Oncology		INREBIC
SA Oncology		IRESSA
SA Oncology		JAKAFI
SA Oncology	Preferred Agents: Ibrance, Verzenio	KISQALI
SA Oncology	Preferred Agents: Ibrance, Verzenio	KISQALI FEMARA 200 DOSE
SA Oncology	Preferred Agents: Ibrance, Verzenio	KISQALI FEMARA 400 DOSE
SA Oncology	Preferred Agents: Ibrance, Verzenio	KISQALI FEMARA 600 DOSE
SA Oncology		KOSELUGO
SA Oncology		lapatinib ditosylate
SA Oncology		LENVIMA 10 MG DAILY DOSE
SA Oncology		LENVIMA 12MG DAILY DOSE
SA Oncology		LENVIMA 14 MG DAILY DOSE
SA Oncology		LENVIMA 18 MG DAILY DOSE
SA Oncology		LENVIMA 20 MG DAILY DOSE
SA Oncology		LENVIMA 24 MG DAILY DOSE
SA Oncology		LENVIMA 4 MG DAILY DOSE

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
SA Oncology		LENVIMA 8 MG DAILY DOSE
SA Oncology		LONSURF
SA Oncology		LORBRENA
SA Oncology		LYNPARZA
SA Oncology		LYSODREN
SA Oncology		MATULANE
SA Oncology		MEKINIST
SA Oncology		MEKTOVI
SA Oncology		NERLYNX
SA Oncology		NEXAVAR
SA Oncology		NINLARO
SA Oncology		NUBEQA
SA Oncology		ODOMZO
SA Oncology		ONUREG
SA Oncology		ORGOVYX
SA Oncology		PEMAZYRE
SA Oncology		PIQRAY 200MG DAILY DOSE
SA Oncology		PIQRAY 250MG DAILY DOSE
SA Oncology		PIQRAY 300MG DAILY DOSE
SA Oncology		POMALYST
SA Oncology		QINLOCK
SA Oncology		RETEVMO
SA Oncology		REVLIMID
SA Oncology		ROZLYTREK
SA Oncology		RUBRACA
SA Oncology		RYDAPT
SA Oncology		SPRYCEL
SA Oncology		STIVARGA
SA Oncology		SUTENT
SA Oncology		SYLATRON
SA Oncology		TABRECTA
SA Oncology		TAFINLAR
SA Oncology		TAGRISSO
SA Oncology		TALZENNA
SA Oncology		TARCEVA
SA Oncology		TARGETIN
SA Oncology	Preferred Agents: generic imatinib, Sprycel	TASIGNA

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
SA Oncology		TAZVERIK
SA Oncology		TEMODAR
SA Oncology		temozolomide
SA Oncology		TEPMETKO
SA Oncology		THALOMID
SA Oncology		TIBSOVO
SA Oncology		tretinoin
SA Oncology		TUKYSA
SA Oncology		TURALIO
SA Oncology		TYKERB
SA Oncology		UKONIQ
SA Oncology		VENCLEXTA
SA Oncology		VENCLEXTA STARTING PACK
SA Oncology		VERZENIO
SA Oncology		VITRAKVI
SA Oncology		VIZIMPRO
SA Oncology		VOTRIENT
SA Oncology		XALKORI
SA Oncology		XELODA
SA Oncology		XOSPATA
SA Oncology		XPOVIO 100 MG ONCE WEEKLY
SA Oncology		XPOVIO 40 MG ONCE WEEKLY
SA Oncology		XPOVIO 40 MG TWICE WEEKLY
SA Oncology		XPOVIO 60 MG ONCE WEEKLY
SA Oncology		XPOVIO 60 MG TWICE WEEKLY
SA Oncology		XPOVIO 80 MG ONCE WEEKLY
SA Oncology		XPOVIO 80 MG TWICE WEEKLY
SA Oncology		XTANDI
SA Oncology		YONSA
SA Oncology		ZEJULA
SA Oncology		ZELBORAF
SA Oncology		ZOLINZA
SA Oncology		ZYDELIG
SA Oncology		ZYKADIA
SA Oncology		ZYTIGA
Samsca		SAMSCA
Samsca		TOLVAPTAN

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
Signifor		SIGNIFOR
SSIA		NUPLAZID
Strensiq		STRENSIQ
Subcutaneous Immune Globulins		CUTAQUIG
Subcutaneous Immune Globulins		CUVITRU
Subcutaneous Immune Globulins		GAMMAGARD LIQUID
Subcutaneous Immune Globulins		GAMMAKED
Subcutaneous Immune Globulins		GAMUNEX-C
Subcutaneous Immune Globulins		HIZENTRA
Subcutaneous Immune Globulins		HYQVIA
Subcutaneous Immune Globulins		XEMBIFY
Substrate Reduction Therapy		CERDELGA
Substrate Reduction Therapy		miglustat
Substrate Reduction Therapy		ZAVESCA
Sucraid		SUCRAID
Sucrafate Suspension		CARAFATE
Sucrafate Suspension		sucrafate
Sunosi		SUNOSI
Thrombopoietin Receptor Agonists		DOPTelet
Thrombopoietin Receptor Agonists		MULPLETA
Thrombopoietin Receptor Agonists		PROMACTA
Thrombopoietin Receptor Agonists		TAVALISSE
Topical AK Basal Cell Carcinoma Warts Agents		ALDARA
Topical AK Basal Cell Carcinoma Warts Agents		CARAC

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
Topical AK Basal Cell Carcinoma Warts Agents		diclofenac sodium
Topical AK Basal Cell Carcinoma Warts Agents		EFUDEX
Topical AK Basal Cell Carcinoma Warts Agents		FLUOROPLEX
Topical AK Basal Cell Carcinoma Warts Agents		FLUOROURACIL
Topical AK Basal Cell Carcinoma Warts Agents		imiquimod
Topical AK Basal Cell Carcinoma Warts Agents		imiquimod pump
Topical AK Basal Cell Carcinoma Warts Agents		KLISYRI
Topical AK Basal Cell Carcinoma Warts Agents		PICATO
Topical AK Basal Cell Carcinoma Warts Agents		TOLAK
Topical AK Basal Cell Carcinoma Warts Agents		ZYCLARA
Topical AK Basal Cell Carcinoma Warts Agents		ZYCLARA PUMP
Topical AK Basal Cell Carcinoma Warts Agents		FLUOROURACIL
Topical Doxepin		DOXEPIN HYDROCHLORIDE
Topical Doxepin		PRUDOXIN
Topical Doxepin		ZONALON
Topiramate ER		QUDEXY XR
Topiramate ER		topiramate er
Topiramate ER		TROKENDI XR
Transmucosal Immediate Release Fentanyl		ABSTRAL
Transmucosal Immediate Release Fentanyl		ACTIQ
Transmucosal Immediate Release Fentanyl		FENTANYL CITRATE
Transmucosal Immediate Release Fentanyl		fentanyl citrate oral transmucosal
Transmucosal Immediate Release Fentanyl		FENTORA

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
Transmucosal Immediate Release Fentanyl		LAZANDA
Transmucosal Immediate Release Fentanyl		SUBSYS
Urea Cycle Disorders		BUPHENYL
Urea Cycle Disorders		RAVICTI
Urea Cycle Disorders		sodium phenylbutyrate
Wakix		WAKIX
Weight Loss Agents		ADIPEX-P
Weight Loss Agents		BELVIQ XR
Weight Loss Agents		BENZPHETAMINE HCL
Weight Loss Agents		CONTRAVE
Weight Loss Agents		diethylpropion hcl
Weight Loss Agents		DIETHYLPROPION HCL ER
Weight Loss Agents		LOMAIRA
Weight Loss Agents		phendimetrazine tartrate
Weight Loss Agents		PHENDIMETRAZINE TARTRATE ER
Weight Loss Agents		phentermine hcl
Weight Loss Agents		phentermine hydrochloride
Weight Loss Agents		QSYMIA
Weight Loss Agents		SAXENDA
Weight Loss Agents		XENICAL
Xermelo		XERMELO
Xhance		XHANCE
Zokinvy		ZOKINVY

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.